Persuasive health communication to increase HIV/HCV testing acceptance
Evaluation of a Persuasive Health Communication Intervention Designed to Increase HIV/HCV Screening Among Emergency Departments Patients Who Currently, Formerly or Never Injected Drugs.
This study is testing whether a short video or a talk with a counselor can encourage adults in emergency rooms who initially said no to get tested for HIV and Hepatitis C.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of South Florida Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT05968573 on ClinicalTrials.gov |
What this trial studies
This intervention aims to improve the acceptance of HIV and Hepatitis C testing among adult patients in emergency departments who initially declined screening. The study will compare the effectiveness of a brief persuasive health communication intervention delivered via video versus by an HIV/HCV counselor. Participants will be stratified based on their history of injection drug use and will be recruited from the Mount Sinai Health System's emergency departments. The trial is designed to be quick, with minimal disruption to patient care, and aims to enroll 2,000 eligible participants over three years.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have declined HIV/HCV screening and are not currently infected with either virus.
Not a fit: Patients who are already HIV or HCV positive, or those who have tested for these viruses in the past 12 months, will not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly increase the rates of HIV and HCV testing among at-risk populations, leading to earlier diagnosis and treatment.
How similar studies have performed: Previous studies have shown that persuasive health communication can effectively increase testing rates for various conditions, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥18 years-old * Speak English or Spanish, and able to provide informed consent for study participation * Not HIV AND HCV infected/Antibody+ (per EHR review and patient report) * Not already participating in a HIV or HCV study (e.g., HIV PrEP, HIV vaccine) * Not tested for HIV OR HCV within the past 12 months (per EHR review and patient report) Exclusion Criteria: * \<18 years old * Unable to speak Spanish or English * HIV or HCV positive * Currently enrolled in another HIV or HCV research study * Has tested for HIV or HCV in the past 12 months
Where this trial is running
New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Roland C Merchant, MD — University of South Florida
- Study coordinator: Roland C Merchant, MD
- Email: Roland.Merchant@mountsinai.org
- Phone: (212) 524-9814
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.